Question 1

What is the catalog number for RHOD CRISPR Knock Out 293T Cell Line (Human)?

Accepted Answer

The catalog number for RHOD CRISPR Knock Out 293T Cell Line (Human) is 39516141.

Question 2

What sizes are available for RHOD CRISPR Knock Out 293T Cell Line (Human)?

Accepted Answer

RHOD CRISPR Knock Out 293T Cell Line (Human) is available in the following size(s): 1x 10^6 Cells / 1.0 mL.

Question 3

Is RHOD CRISPR Knock Out 293T Cell Line (Human) in stock?

Accepted Answer

RHOD CRISPR Knock Out 293T Cell Line (Human) is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Is this product suitable for live cell imaging?

Accepted Answer

Suitability for live cell imaging depends on the specific reagent and conjugate used. Check the datasheet for imaging-specific validation, or contact us for guidance.

Question 5

Is this product covered by a money-back guarantee?

Accepted Answer

Yes, we guarantee a full refund or store credit if this product arrives damaged beyond usability, or has a genuine performance issue under proper usage and storage, provided you report it immediately with evidence. Claims after the expiration date or due to improper storage after receipt are excluded.

Question 6

Can this product be used for diagnostic or therapeutic purposes?

Accepted Answer

No. This product, like all items we supply, is intended for research laboratory use only and must not be used for diagnostics, therapeutics, treatment, or consumption by humans or animals.

RHOD CRISPR Knock Out 293T Cell Line (Human)

Product Specifications

Gene Name

Gene Aliases

Accession Number

Reactivity

Shipping Conditions

Storage Conditions

Frequently Asked Questions

Explore Other Products

Cathepsin D (Tumor Marker) (CTSD/2781), CF740 conjugate, 0.1mg/mL

Prolactin Receptor (hPRL Receptor) (PRLR/3785R), CF740 conjugate, 0.1mg/mL

Cytokeratin 5 (KRT5) (Basal, Myoepithelial & Mesothelial Cell Marker) (KRT5/3594), CF647 conjugate, 0.1mg/mL

AKT1 (Prognostic Marker for Neuroendocrine Tumors) (AKT1/2491), CF405S conjugate, 0.1mg/mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2745), CF740 conjugate, 0.1mg/mL

Androgen Receptor (DHTR/882), CF488A conjugate, 0.1mg/mL